BRD4 and pulmonary arterial hypertension: The only drug to date to target remodelling per se is the PDGF receptor kinase inhibitor, imatanib, which reduced pulmonary vascular resistance in patients with severe PAH but its use was associated with intolerable side effects.23, 24 We show that the BET mimetic, JQ1+ (which has a higher affinity for BRD4 than other Brds25), inhibits key inflammatory processes in human primary HPMECs.